Bayer Subsidiary Begins Phase 2 Trial for Colorectal Cancer Drug
What happened
Vividion Therapeutics, a subsidiary of Bayer, began a Phase 2 clinical study for VVD-214, an oral Werner helicase (WRN) inhibitor. The randomized trial will test VVD-214 combined with pembrolizumab as a first-line treatment for patients with advanced microsatellite instability-high (MSI-high) or deficient mismatch repair (dMMR) colorectal cancer.
From finanznachrichten.de
Why it matters
This study expands the clinical use of VVD-214 into earlier treatment lines for advanced colorectal cancer. Colorectal cancer is an area of significant medical need, with approximately 15 percent of tumors being MSI-high.
From finanznachrichten.de
Who's involved
- BAYERParent company of Vividion Therapeutics, which is conducting the clinical trial.
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- BAYERSpeculative
Bayer might see increased future revenue potential due to the clinical success of Vividion's pipeline.